项目整合精选

聚焦新型临床类新产品的整合与转化. 在创新药研发领域，传统的“单一产品、单打独斗”模式正在被一种更系统化的“项目整合”思维所取代。项目整合的核心，在于将散落在研发早期、中期的创新资产，通过资金、临床资源、产业生态等多维度要素的有机组合，实现从“科学发现”到“临床价值”，再到“商业成功”的跨越。研发与商业的战略整合：从“资产思维”到“组合思维”它要求我们超越单个分子的视野，拥抱一个由技术创新、临床需求、资本支持和商业洞察共同构成的复杂网络。在这个网络中，成功的标准不再是单一的“获批上市”，而是能否通过高效的整合，将科学上的突破，转化为临床上真正可及、商业上可持续、能够惠及患者的解决方案。近年来，药物发现已从传统的小分子化药拓展至更多元的分子类型，这些新型API在项目整合中呈现出独特的开发范式，项目整合的核心挑战在于递送系统的设计与肝外靶向能力的突破。
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

项目整合精选

HMR-1556

N-[(3R,4S)-3,4-二氢-3-羟基-2,2-二甲基-6-(4,4,4-三氟丁氧基)-2H-1-苯并吡喃-4-基]-N-甲基甲磺酰胺Chemical Name: (+)-N-[2,2-Dimethyl-3(R)-hydroxy-6-(4,4,4-trifluorobutoxy)-3,4-dihydro-2H-1-benzopyran-4(S)-yl]-N-methylmethanesulf...
参考文献标题:Sulphonamide substd.benzopyran derivs.,process of preparation,their use as medicines and pharmaceutical compsns.containing them
文献作者:Lang,H.J.; Gerlach,U.; Weldmann,K.; Brendel,J.(Aventis Pharma Deutschland GmbH)
参考来源:CA 2252733; DE 19748469; EP 0913396; JP 1999222485; US 6008245

Carabersat, SB-204269

N-[(3R,4S)-6-乙酰基-3,4-二氢-3-羟基-2,2-二甲基-2H-1-苯并吡喃-4-基]-4-氟-苯甲酰胺Chemical Name: (+)-(3R,4S)-N-(6-Acetyl-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4-fluorobenzamide
CAS No. 184653-84-7, 17...
参考文献标题:Novel receptor
文献作者:Herdon,H.J.; Jerman,J.C.; Chan,W.N.(GlaxoSmithKline plc)
参考来源:JP 1998511083; US 5985334; WO 9618650

CL-331928(monohydrochloride), CL-331002, DMG-DMDOT

N-[(5aR,6aS,7S,9Z,10aS)-9-(氨基-羟基甲亚基)-7-二甲基氨基-1,10a,12-三羟基-8,10,11-三氧代-5a,6,6a,7-四氢-5H-并四苯-2-基]-2-二甲基氨基乙酰胺Chemical Name: (4S,4aS,11aR,12aS)-1-(Dimethylamino)-8-[2-(dimethylamino)acetamido]-2,4a,5,7-tet...
参考文献标题:9-(Substd.glycyl)amido-6-demethyl-6-deoxytetracyclines as antibiotic agents
文献作者:Sum,P.-E.; Lee,V.J.; Testa,R.T.(American Cyanamid Co.)
参考来源:EP 0582829; JP 1994199758

AZD-6126, ZD-6126, ANG-453

N-[(5S)-6,7-二氢-9,10,11-三甲氧基-3-(磷酰氧基)-5H-二苯并[a,c]环庚烯-5-基]乙酰胺Chemical Name: 5(S)-Acetamido-9,10,11-trimethoxy-6,7-dihydro-5H-dibenzo[a,c]cyclohepten-3-yl dihydrogen phosphate
CAS No. 219923-05-4
项...
参考文献标题:Use of colchinol derivs.as vascular damaging agents
文献作者:Dougherty,G.(Angiogene Pharmaceuticals Ltd.)
参考来源:WO 9902166

NSC-624548, HO-221

N-[[4-(5-溴嘧啶-2-基)氧基-3-氯苯基]氨基甲酰]-2-(羟基-氧代氨基)苯甲酰胺Chemical Name: N-(2-Nitrobenzoyl)-N'-[4-(5-bromo-2-pyrimidinyloxy)-3-chlorophenyl]urea; N-[4-(5-Bromo-2-pyrimidinyloxy)-3-chlorophenyl]-N'-(2-nitrobenzoy...
参考文献标题:Benzoyl urea cpds.,process for their production,
文献作者:Haga,T.; Kondo,N.; Koyanagi,T.; Nakajima,T.; Sugi,H.; Watanabe,M.; Yamada,N.; Yokoyama,K.(Ishihara Sangyo Kaisha,Ltd.)
参考来源:CH 671576; EP 0192235; FR 2577551; GB 2171695; US 4727077

NSC-639829

N-[[4-(5-溴嘧啶-2-基)氧基-3-甲基苯基]氨基甲酰]-2-二甲基氨基苯甲酰胺Chemical Name: N-[4-(5-Bromo-2-pyrimidinyloxy)-3-methylphenyl]-N'-[2-(dimethylamino)benzoyl]urea
CAS No. 134742-19-1
项目整合开发状态: Phase I
项目研究机构: Ishi...
参考文献标题:Substd.benzoylurea cpds.or their salts,processes for their production and antitumour compsns.containing them
文献作者:Haga,T.; Yamada,N.; Sugi,H.; Koyanagi,T.; Okada,H.; Ishihara,Y.(Ishihara Sangyo Kaisha,Ltd.)
参考来源:AU 9059832; EP 0413977; JP 1992029979; US 5102884

PD-173212

N-[[4-叔丁基苯基]甲基]-N-甲基-L-亮氨酰-N-叔丁基-O-苄基-L-酪氨酰胺Chemical Name: N-(4-tert-Butylbenzyl)-N-methyl-L-leucyl-4-O-(benzyl)-L-tyrosine tert-butylamide
CAS No. 217171-01-2
项目整合开发状态: Preclinical
项目研究机构: E...
参考文献标题:Substd.peptidylamine calcium channel blockers
文献作者:Szoke,B.G.; Rafferty,M.F.; Silva,D.F.; Song,Y.; Malone,T.C.; Hu,L.-Y.; Urge,L.; Nadasdi,L.; Ryder,T.R.(Neurex Corp.; Pfizer Inc.)
参考来源:WO 9854123

Thymectacin, NB-1011, NB-101

N-[[5-[(E)-2-溴乙烯基]-2'-脱氧尿苷-5'-O-基](苯氧基)磷酰]-L-丙氨酸甲酯Chemical Name: N-[[5-[(E)-2-Bromovinyl]-2'-deoxyuridin-5'-O-yl](phenoxy)phosphoryl]-L-alanine methyl ester
CAS No. 232925-18-7
项目整合开发状态: Phase I...
参考文献标题:Enzyme catalyzed therapeutic agents
文献作者:Shepard,H.M.(NewBiotics,Inc.)
参考来源:EP 1167972; JP 2001220397; US 6245750; WO 9937753

D-t-EtDO-P4

N-[1-(2,3-二氢-1,4-苯并二氧杂环己-6-基)-1-羟基-3-(1-吡咯烷基)-2-丙基]十六烷酰胺Chemical Name: N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]hexadecanamide
CAS No. 245329-78-6
...
参考文献标题:Synthesis of UDP-glucose: N-Acylsphingosine glucosyltransferase inhibitors
文献作者:Hirth,B.H.; Siegel,C.(Genzyme Corp.)
参考来源:US 2003050299; WO 0308399

ABT-518

N-[1(S)-[2,2-二甲基-1,3-二氧基-4(S)-基]-2-[4-[4-(三氟甲氧基)苯氧基]苯基磺酰]-N-羟基甲酰胺Chemical Name: N-[1(S)-[2,2-Dimethyl-1,3-dioxolan-4(S)-yl]-2-[4-[4-(trifluoromethoxy)phenoxy]phenylsulfonyl]ethyl]-N-hydroxyformamide 参考文献标题:Reverse hydroxamate inhibitors of matrix metalloproteinases
文献作者:Curtin,M.L.; Davidsen,S.K.; Michaelides,M.R.; Steinman,D.H.; Dai,Y.; Heyman,H.R.; Holmes,J.H.(Abbott Laboratories Inc.)
参考来源:WO 0044739